{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T05:20:15Z","timestamp":1739510415788,"version":"3.37.0"},"reference-count":20,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2025,2,12]]},"DOI":"10.18632\/oncotarget.28687","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T02:37:06Z","timestamp":1739414226000},"page":"67-78","source":"Crossref","is-referenced-by-count":0,"title":["Could Panitumumab with very low dose Capecitabine be an option as a maintenance regimen"],"prefix":"10.18632","volume":"16","author":[{"given":"Doaa A.","family":"Gamal","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Assiut University Hospital, Assiut 71515, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiat","family":"Morsy","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Assiut University Hospital, Assiut 71515, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mervat","family":"Omar","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Assiut University Hospital, Assiut 71515, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jcol.2017.09.418","article-title":"Epidemiology and survival of colon cancer among Egyptians: a retrospective study","volume":"3","author":"Hamdy","year":"2018","journal-title":"Journal of Coloproctology"},{"key":"2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"2","author":"Koralewski","year":"2009","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1200\/JCO.18.02258","article-title":"Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB\/SWOG 80405 (Alliance)","volume":"3","author":"Tejpar","year":"2019","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"e2011036","DOI":"10.1001\/jamanetworkopen.2020.11036","article-title":"Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial","volume":"3","author":"Yuan","year":"2020","journal-title":"JAMA Netw Open"},{"key":"5","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/ijc.32110","article-title":"Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials","volume":"14","author":"Douillard","year":"2019","journal-title":"Int J Cancer"},{"key":"6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1634\/theoncologist.2011-0249","article-title":"First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study","volume":"1","author":"Benavides","year":"2012","journal-title":"Oncologist"},{"key":"7","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","article-title":"Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group","volume":"38","author":"Nieboer","year":"2015","journal-title":"Lancet"},{"key":"8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ejca.2018.06.024","article-title":"First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study","volume":"10","author":"Rivera","year":"2018","journal-title":"Eur J Cancer"},{"key":"9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/annonc\/mdm399","article-title":"An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy","volume":"1","author":"Peeters","year":"2008","journal-title":"Ann Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/1120009X.2021.1920247","article-title":"Performance of capecitabine in novel combination therapies in colorectal cancer","volume":"3","author":"Nemati","year":"2021","journal-title":"J Chemother"},{"key":"11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"36","author":"Ruff","year":"2013","journal-title":"N Engl J Med"},{"key":"12","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00384-017-2800-1","article-title":"Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma","volume":"3","author":"Schwartzberg","year":"2017","journal-title":"Int J Colorectal Dis"},{"key":"13","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","article-title":"PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer","volume":"3","author":"Go","year":"2014","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"2","author":"Ruff","year":"2010","journal-title":"J Clin Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"e23719","DOI":"10.1097\/MD.0000000000023719","article-title":"Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients","volume":"9","author":"Miao","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","article-title":"OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study","volume":"2","author":"Louvet","year":"2006","journal-title":"J Clin Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/jamaoncol.2018.4465","article-title":"Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial","volume":"5","author":"Hebbar","year":"2019","journal-title":"JAMA Oncol"},{"key":"18","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jamaoncol.2019.1467","article-title":"Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial","volume":"5","author":"Clavarezza","year":"2019","journal-title":"JAMA Oncol"},{"key":"19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1200\/JCO.21.01332","article-title":"Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy inWild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)","volume":"4","author":"Stahler","year":"2022","journal-title":"J Clin Oncol"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.3543","article-title":"Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS\/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO","volume":"3","author":"Di Fabio","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28687","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T13:19:08Z","timestamp":1739452748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2,12]]}},"alternative-id":["28687"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28687","relation":{},"ISSN":["1949-2553"],"issn-type":[{"type":"electronic","value":"1949-2553"}],"subject":[],"published":{"date-parts":[[2025,2,12]]}}}